Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furaprevir, Yimitasvir, and Ribavirin in HCV Genotype 1
NCT04155515Phase 3Completed
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals
- Start
- Jun 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of furaprevir and yimitasvir in hepatitis C (HCV) (2 arms), sponsored by Dongguan HEC TaiGen Biopharmaceuticals. Primary endpoint: Proportion of antiviral efficacy (HCV RNA < LLOQ). Started Jun 2019; status: completed.
02
Drugs
furapreviryimitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04155515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155515.